Evotec SE — Regulatory Filings 2015

Dec 10, 2015

News Details

Corporate | 10 December 2015 07:30

Evotec receives important pre-clinical milestones as part of its multi-target alliance with Bayer HealthCare

DGAP-News: Evotec AG / Key word(s): Miscellaneous

2015-12-10 / 07:30
The issuer is solely responsible for the content of this announcement.

---

Hamburg, Germany - 10 December 2015: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) announced today that its multi-target
collaboration with Bayer HealthCare ("Bayer") has reached two important
pre-clinical milestones for the transition of two projects from the
alliance portfolio into late-stage discovery and pre-clinical development
for the treatment of endometriosis.

These milestones were achieved under the strategic alliance between Evotec
and Bayer entered in October 2012. The goal of this collaboration is to
develop three clinical candidates within the five-year alliance. Both
parties contribute innovative drug targets and high-quality technology
infrastructures and share the responsibility for early research and
pre-clinical characterisation of potential clinical candidates in the
disease area of endometriosis.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented:
"Endometriosis is a truly debilitating disease for a large population of
women. These milestones represent further good progress in addressing both
the underlying inflammation as well as the resulting pain and reflect well
on the tremendous combined efforts of both teams of scientists from Evotec
and Bayer. We look forward to continuing this productive work and focusing
our efforts on bringing forward new drug candidates to tackle this
significant disease."

Financial details were not disclosed.

ABOUT ENDOMETRIOSIS
Endometriosis affects an estimated 176 million women worldwide or 10% of
women of reproductive age. It is caused by the abnormal growth of tissue
similar to that which lines the uterus (endometrial tissue) in locations
outside of the uterine cavity, where it causes ectopic lesion growth and
debilitating pain. Endometrial growth is commonly found on the ovaries and
pelvic peritoneum, potentially involving other organs of the pelvic cavity
as e.g. bladder, bowel, and the rectovaginal space. There is no known cure
for endometriosis and most available drug treatments have certain
limitations. Endometriosis is a highly complex and heterogeneous disease
and there is still a high unmet medical need for innovative therapies which
address the individual needs of affected women. The disease can greatly
impact a woman's social, professional and personal life, and women with
endometriosis often experience a higher incidence of depression and
emotional distress due to the uncertainty of diagnosis, unpredictability of
symptoms and living a normal life. Find more information at
http://endometriosisfoundation.org or http://endometriosis-league.eu/en.

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain, metabolic
diseases as well as oncology, inflammation and infectious diseases. Evotec
has long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim and
MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the
field of depression and with Roche in the field of Alzheimer's disease. For
additional information please go to http://www.evotec.com/.

FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this press release. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond
our control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations
or any change in events, conditions or circumstances on which any such
statement is based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com

---

2015-12-10 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart

 End of News    DGAP News Service